by optimindpharma | Sep 20, 2022 | Press Releases
Optimind looks to accelerate the adoption of the MindSetting(TM) TRIP Protocol for ketamine-assisted therapy and other psychedelic enhanced psychotherapy modalities. Toronto, Ontario–(Newsfile Corp. – September 20, 2022) – Optimind Pharma...
by optimindpharma | Aug 10, 2022 | Press Releases
Optimind Provides Update on Health Canada’s Dealer License under Joint-Venture with Manitari Pharma Manitari Pharma received approval to begin construction of Security Level 3 safe + grow rooms Manitari Pharma is one step closer to obtaining Controlled Substances...
by optimindpharma | Aug 4, 2022 | Press Releases
Optimind Pharma Commences Trading on the CSE Under Ticker Symbol OMND TORONTO – Optimind Pharma Corp. (CSE:OMND (“Optimind” or the “Company”) today announced its commencement of trading on the CSE (Canadian Securities Exchange) under ticker symbol “OMND”. Optimind...
by optimindpharma | Aug 2, 2022 | Press Releases
Optimind Pharma Announces Closing of Reverse Takeover Transaction Toronto, Ontario–(Newsfile Corp. – July 29, 2022) – Optimind Pharma Corp. (“Optimind” or the “Company”) announces the successful closing of its previously...
Recent Comments